Navigation Links
Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
Date:5/9/2008

Growth of promoted products and reduced operating costs drive solid

earnings growth.

ST. DAVID'S, Bermuda, May 9 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced its results for the quarter ended March 31, 2008. Revenue in the quarter ended March 31, 2008 totaled $229.5 million, an increase of 5.1%, over the prior year quarter. The primary drivers of the increase in revenue were the net sales of our promoted products LOESTRIN 24 FE, DORYX, TACLONEX and FEMCON FE, which together contributed $34.4 million of revenue growth for the quarter ended March 31, 2008 compared to the prior year quarter. The growth delivered by these products was offset primarily by a significant decline in ESTROSTEP FE revenue due to generic competition.

The Company reported net income of $33.7 million ($0.13 per diluted share) in the quarter ended March 31, 2008, compared with a net loss of $4.5 million ($0.02 per diluted share) in the prior year quarter. Cash net income ("CNI") in the quarter ended March 31, 2008 was $82.9 million, an increase of $31.9 million, compared to $51.0 million in the prior year quarter.

References in this release to "cash net income" or "CNI" mean the Company's net income/(loss) adjusted for the after-tax effects of two non-cash items: amortization of intangible assets and amortization (or write-off) of deferred loan costs related to the Company's debt. Reconciliations from the Company's reported results in accordance with US GAAP to cash net income, adjusted cash net income and adjusted EBITDA for all periods are presented in the tables at the end of this press release.

Revenue

Revenue in the quarter ended March 31, 2008 was $229.5 million
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
2. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
7. Warner Chilcott Reports the Death of Its Director James Andress
8. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
9. Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2008 Financial Results
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. QMed, Inc. Reports July Medicare SNP Enrollments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., , BOSTON, Nov. 25 ...e H1N1 virus, genomic data from the 1918 pandemic ...the current H1N1 pandemic, today issued its latest...hows that the lethality of the H1N1 ("Swine Flu") ...during the virus,s current outbreak in the spring ...
(Date:11/25/2009)..., , ,, BOCA RATON, ... 2009 has been a painful year. Not so for BodyLogi...work of expert physicians specializing exclusively...as grown the number of physicians in its netwo...ns - and is in progress to add more physician-own...
(Date:11/25/2009)..., , BEIJING, Nov. 25 /PRNewswir...developer and provider of vaccines, announced toda...to establish Sinovac (Dalian) Vaccine,Technology C...evelop, produce,and commercialize human-use vaccin...rience in developing and commercializing world-cla...
(Date:11/25/2009)..., , SAN DIEGO, Nov. 25 /PRNewswire-FirstC...nnounced today that Barry D. Quart, Pharm.D., pres... the Piper Jaffray 21st Annual Health Care Confere...er Jaffray 21st Annual Health Care Conference,Date....m. Eastern Time,Location: The New York Palace Ho...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...on Monday, February 25, 2008 at ...Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopha...velopment and commercialization of medically impor...nt of life-threatening,diseases, including diabete...results for the fourth quarter and year ended Dece...
...ht,Corporation (Nasdaq: PHST ), a leading provide...y services for optimizing clinical drug,developmen...sup and,Lamont,s 2008 Emerging Growth Stock Confer...mporary resort in Orlando, FL. Shawn O,Connor, Pha... Senior Vice President and CFO,will present the co...
...International, Inc. (Pink Sheets: BCLN) announced ...nvestment forum presented by Bluechip Capital,Inc....Mission Bay Hilton in,San Diego, California., Jam...rnational stated:,"The Bluechip Capital investment...present our compelling story to the investor commu...
Other Biology Technology:Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 6Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference 2Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum 2Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum 3
(Date:11/26/2009)... What are the bare essentials of life, the indisp...t can survive on its own? Can we describe the mole...ire organism functions as a system? These are just...rship between the European Molecular Biology Labor...e de Regulacio Genmica (CRG) in Barcelona, Spain, ...
(Date:11/25/2009)...e California Institute of Technology (Caltech) hav...ehavior in the fruit fly, Drosophila melanogaster...e relationship between the neurotransmitter dopami...DHD), are described in the December issue of the j...ns only about 20,000 neurons and has long been con...
(Date:11/25/2009)... easy lives. In addition to mammalian immune syste...s called bacteriophages, viruses that kill half th...cteria and another class of microorganisms called ...such as deep-sea volcanic vents) manage just fine,...efense system that helps protect them from many vi...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 1Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 3Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 4Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 5Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 6Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 7Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 8Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 9Major clinical study rejects cancer safety fears of most common heartburn treatment 56590 1Major clinical study rejects cancer safety fears of most common heartburn treatment 56590 2Four fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 56586 1Four fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 56586 2Four fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 56586 3Four fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 56586 4
...pean BioAlpine Convention 2008, an international e...luster Rhne-Alpes (France), Piemonte (Italy) and ...rs and professionals from academia and industry in...ings in the fields of Bioinformatics and Proteomic...s in the technology and application of proteomics ...
...IRREGULAR HEARTBEAT MAY DEVELOP AFTER LUNG TRANSPL...atients receiving donated lungs may develop arrhyt...from Baylor College of Medicine in Texas reviewed ...06 and 2007. Of the 75 patients who underwent lung...in 30 days of transplantation. The most common arr...
...E, Mass. -- Drawing on records dating back to the ...vard University have found that different plant fa...climate change in strikingly different ways. Some ...g have included beloved species like lilies, orchi...ars this week in the Proceedings of the National ...
Other Biology News:Bridging public and private research on bioinformatics and proteomics 2New cardiology research presented at CHEST 2008 2New cardiology research presented at CHEST 2008 3New cardiology research presented at CHEST 2008 4Effects of climate change vary greatly across plant families 2
Anti-AANAT Antibody, Unconjugated from CHEMICON
Mouse Anti-TUP1 Monoclonal Antibody, Unconjugated, Clone 10 from Exalpha Biologicals, Inc.
Mouse Anti-Human NANS Monoclonal Antibody, Unconjugated, Clone 3G6 from ABR-Affinity BioReagents
Mouse Anti-C2 Monoclonal Antibody, Unconjugated, Clone 050-04 from Abcam
Biology Products: